MW 398.5 Da, Purity >=99%. Sunitinib is a free base form of Sunitinib malate.
A CSF-1 receptor kinase inhibitor .
75 kDa bromodomain protein, AAG6, ACEE, ACES_HUMAN, ARACHE, Acetylcholinesterase, Aging associated gene 6, Aland island eye disease (Forsius Eriksson ocular albinism, ocular albinism type 2), Apoptosis related acetylcholinesterase, BP75, BRD7_HUMAN, BSK, Brain-specific kinase, Bromodomain containing 7, Bromodomain containing 9, Bromodomain containing protein 9, Bromodomain-containing protein 7, CAC1C_HUMAN, CAC1D_HUMAN, CAC1F_HUMAN, CAC1S_HUMAN, CACH 2, CACH1, CACH3, CACN 2, CACN1, CACN4, CACNA 1D, CACNAF, CACNAF1, CACNL1A1, CACNL1A2, CACNL1A3, CCHL1A1, CCHL1A2, CCHL1A3, CEK 7, CELTIX 1, COD 3, CORDX, CORDX 3, CSNB2A, CSNBX 2, CaV1.2, Cach1b, Calcium channel, Calcium channel L type alpha 1 polypeptide isoform 1 cardiac muscle, Calcium channel L type alpha 1 polypeptide isoform 2, Calcium channel cardic dihydropyridine sensitive alpha 1 subunit, Calcium channel neuroendocrine/brain type alpha 1 subunit, Calcium channel voltage dependent L type alpha 1, Calcium channel voltage dependent L type alpha 1C subunit, Calcium channel voltage dependent L type alpha 1D subunit, Calcium channel voltage dependent L type alpha 1F subunit, Calcium channel voltage dependent alpha 1F subunit, Calcium channel, L type, alpha 1 polypeptide, isoform 3, skeletal, Calcium channel, L type, alpha 1 polypeptide, isoform 3, skeletal muscle, Calcium channel, L type, alpha 1 polypeptide, isoform 3, skeletal muscle, hypokalemic periodic paralysis, Calcium channel, skeletal muscle dihydropyridine sensitive , alpha 1 subunit, Calcium channel, voltage dependent, L type, alpha 1S subunit, Calcium channel, voltage-dependent, L type, alpha 1S subunit, b, Cav1.1, Cav1.3, Cav1.4, Cav1.4alpha1, DHPR alpha 1, DHPR alpha 1 subunit, DKFZp434D0711, DKFZp686L0539, Dihydropyridine receptor, Dihydropyridine sensitive L type calcium channel alpha 1 subunit, EHK-1, EK7, EPH homology kinase 1, EPH-like kinase 7, EPHA5_HUMAN, Eck like sequence 1, Els 1, Ephrin type-A receptor 5, FLJ13441, FLJ42439, HEK 7, HOKPP, HypoPP, JM 8, JMC 8, KIAA0213, KPCA_HUMAN, L type, LAVS3040, LQT8, M3K4_HUMAN, MAP three kinase 1, MAP/ERK kinase kinase 4, MAPK/ERK kinase kinase 4, MAPKKK4, MEK kinase 4, MEKK 4, MHS5, MTK1, Malignant hyperthermia susceptibility 5, Mitogen-activated protein kinase kinase kinase 4, N-ACHE, NAG4, OTTHUMP00000025825, PASNA, PIM2_HUMAN, PKC-A, PKC-alpha, PRKACA, PRKCA, PRO0412, PRO9856, Pim 2 oncogene, Pim-2h, Protein CELTIX-1, Protein Kinase C alpha, Protein kinase C alpha type, Proto Oncogene PIM2, Proto-oncogene Pim-2 (serine threonine kinase), ROB1, RP3-473J16.4, Receptor protein tyrosine kinase HEK 7, Rek 7, Rhabdomyosarcoma antigen MU RMS 40.8, SANDD, SSK2/SSK22 MAP kinase kinase kinase, yeast, homolog of, Sarcoma antigen NY SAR 29, Serine/threonine kinase PIM2, Serine/threonine-protein kinase Pim-2, TS, TTPP1, TYRO 4, Tyrosine protein kinase receptor EHK 1, UNQ3040, Voltage dependent L type calcium channel alpha 1C subunit, Voltage ependent L ype calcium channel subunit alpha F, Voltage gated L type calcium channel Cav1.2 alpha 1 subunit, splice variant 10*, Voltage gated calcium channel alpha 1 subunit, Voltage gated calcium channel alpha 1F subunit, Voltage gated calcium channel alpha subunit Cav1.2, Voltage gated calcium channel alpha subunit Cav1.3, Voltage gated calcium channel subunit alpha Cav1.4, Voltage-dependent L-type calcium channel subunit alpha-1C, Voltage-dependent L-type calcium channel subunit alpha-1D, Voltage-dependent L-type calcium channel subunit alpha-1S, Voltage-gated calcium channel subunit alpha Cav1.1, Voltage-gated calcium channel subunit alpha Cav1.2, Voltage-gated calcium channel subunit alpha Cav1.3, YT, YT blood group, aPKC, alpha-1 polypeptide, cardiac muscle, dJ473J16.1 (mitogen-activated protein kinase kinase kinase 4), fmd, isoform 1, isoform 2, isoform 3, predicted protein of HQ0412, sj
MW 398.5 Da, Purity >=99%. Sunitinib is a free base form of Sunitinib malate.
A CSF-1 receptor kinase inhibitor .
DMSO (40 mg/ml).
Sunitinib is a free base form of Sunitinib malate.
A CSF-1 receptor kinase inhibitor
PKC alpha also known as protein kinase C alpha is a serine/threonine-specific protein kinase with a molecular mass of around 77 kDa. It participates in regulating various cellular functions by phosphorylating serine and threonine residues on target proteins. PKC alpha is widely expressed in many tissues including the brain and heart indicating its diverse role in cellular signaling. Acetylcholinesterase responsible for breaking down the neurotransmitter acetylcholine is found at neuromuscular junctions and synapses vital for muscle function. CACNA1C is a gene encoding a voltage-dependent calcium channel part of the alpha-1 subunit. Eph receptor A5 also known as BSK involves cell positioning and migration. PIM2 is a proto-oncogene with roles in cell cycle regulation. Both BRD7 and BRD9 interact with chromatin structure affecting gene transcription. CACNA1S and CACNA1F are calcium channel components with CACNA1S found in skeletal muscle and CACNA1F in the retina. CaV1.3 in the same calcium channel family influences heart and brain function. MAP3K4 regulates signal transduction associated with cellular stress responses. Scn1a along with the pan sodium channel and SCN3A play critical roles in the initiation and propagation of action potentials in neurons.
These targets play substantial roles in cellular communication signaling and homeostasis. Protein Kinase C alpha participates in signal transduction related to cell growth and differentiation. Acetylcholinesterase modulates neurotransmission by degrading acetylcholine. CACNA1C along with CACNA1S and CACNA1F form part of important calcium channels affecting excitatory processes in heart and muscle function. Eph receptor A5 influences neuronal development and tissue patterning. PIM2 supports cell survival and proliferation. BRD7 and BRD9 impact chromatin remodeling essential for transcriptional regulation. MAP3K4 contributes to signaling pathways related to stress responses. Scn1a and SCN3A integral to sodium channel operation support neuronal excitability.
Many of these proteins are key in significant signaling cascades. PKC alpha and MAP3K4 both participate in the MAPK pathway affecting responses to growth factors and stress stimuli. PKC alpha often interacts with substrates like RAF kinases within this pathway. Calcium channels including CACNA1C and CaV1.3 are involved in the calcium signaling pathway integral to cellular excitability and homeostasis. Proteins linked with these pathways such as calmodulin help mediate the response to changes in intracellular calcium levels. Scn1a and SCN3A ensure proper neuronal transmission by facilitating sodium influx necessary for action potentials.
Many of these targets have connections to significant health issues. Mutations in CACNA1C are associated with Timothy syndrome a rare cardiac and neurological disorder while changes in SCN1A relate to epilepsy disorders such as Dravet syndrome. Abnormal PKC alpha activity is linked to various cancers due to its role in cell proliferation. Eph receptor A5 implicates neurological disorders due to its role in brain development interacting with ephrin ligands facilitating neurogenesis. Altered acetylcholinesterase activity is evident in Alzheimer's disease contributing to neurotransmitter imbalance. PIM2 overexpression may lead to hematological cancers through its cell survival signaling pathways.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com